請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68248完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 張逸良(Yih-Leong Chang) | |
| dc.contributor.author | Chung-Yu Chen | en |
| dc.contributor.author | 陳崇裕 | zh_TW |
| dc.date.accessioned | 2021-06-17T02:15:42Z | - |
| dc.date.available | 2018-02-22 | |
| dc.date.copyright | 2018-02-22 | |
| dc.date.issued | 2017 | |
| dc.date.submitted | 2017-10-13 | |
| dc.identifier.citation | Azzoli, C. G., et al. (2009). 'American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non–small-cell lung cancer.' Journal of clinical oncology27(36): 6251-6266.
Buqué, A., et al. (2013). 'Thymidylate synthase expression determines pemetrexed targets and resistance development in tumour cells.' PloS one8(5): e63338. Burdett, S., et al. (2008). 'NSCLC Meta analyses collaborative group: Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and metaanalysis of individual patient data from 16 randomized controlled trials.' J Clin Oncol26(28): 4617-4625. Ceppi, P., et al. (2006). 'Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase.' Cancer107(7): 1589-1596. Chamizo, C., et al. (2015). 'Thymidylate synthase expression as a predictive biomarker of pemetrexed sensitivity in advanced non-small cell lung cancer.' BMC pulmonary medicine15(1): 132. Chen, C.-Y., et al. (2011). 'Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.' Lung Cancer74(1): 132-138. Chen, S., et al. (2010). 'The platinum-based treatments for advanced non-small cell lung cancer, is low/negative ERCC1 expression better than high/positive ERCC1 expression? A meta-analysis.' Lung Cancer70(1): 63-70. Christoph, D. C., et al. (2013). 'Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non–small-cell lung cancer treated with pemetrexed.' Journal of thoracic oncology8(1): 19-30. Ciuleanu, T., et al. (2009). 'Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study.' The Lancet374(9699): 1432-1440. Eisenhauer, E., et al. (2009). 'New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).' European journal of cancer45(2): 228-247. Emdad, L., et al. (2007). 'Astrocyte elevated gene-1: recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration.' Pharmacology & therapeutics114(2): 155-170. Ettinger, D. S., et al. (2012). 'Non–small cell lung cancer.' Journal of the National Comprehensive Cancer Network10(10): 1236-1271. Hanna, N., et al. (2004). 'Randomized phase III trial of pemetrexed versus docetaxel in patients with non–small-cell lung cancer previously treated with chemotherapy.' Journal of clinical oncology22(9): 1589-1597. Hu, G., et al. (2009). 'MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer.' Cancer cell15(1): 9-20. Hu, G., et al. (2009). 'The multifaceted role of MTDH/AEG-1 in cancer progression.' Clinical cancer research15(18): 5615-5620. Huang, Y. and L. P. Li (2014). 'Progress of cancer research on astrocyte elevated gene‑1/Metadherin.' Oncology letters8(2): 493-501. Howlader, N. et al. (2015). 'SEER cancer statistics review, 1975-2012'[Internet] Bethesda, MD: National Cancer Institute; 2013.Available from: http://seer.cancer.gov/csr/1975_2012/ Jiang, B., et al. (2016). 'B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway.' Tumor Biology37(7): 9465-9472. Karachaliou, N., et al. (2014). 'Predicting resistance by selection of signaling pathways.' Translational lung cancer research3(2): 107. Kasai, D., et al. (2013). 'Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.' Anticancer research33(5): 1935-1940. Ke, Z.-f., et al. (2013). 'AEG-1 expression characteristics in human non-small cell lung cancer and its relationship with apoptosis.' Medical Oncology30(1): 383. Krawczyk, P., et al. (2014). 'Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.' Journal of cancer research and clinical oncology140(12): 2047-2057. Lee, S.-G., et al. (2006). 'Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc.' Proceedings of the National Academy of Sciences103(46): 17390-17395. Lee, S. H., et al. (2013). 'Thymidylate synthase and ERCC1 as predictive markers in patients with pulmonary adenocarcinoma treated with pemetrexed and cisplatin.' Lung Cancer81(1): 102-108. Liu, H., et al. (2009). 'Knockdown of astrocyte elevated gene-1 inhibits proliferation and enhancing chemo-sensitivity to cisplatin or doxorubicin in neuroblastoma cells.' Journal of Experimental & Clinical Cancer Research28(1): 19. Liu, X., et al. (2014). 'Knockdown of astrocyte elevated gene-1 (AEG-1) in cervical cancer cells decreases their invasiveness, epithelial to mesenchymal transition, and chemoresistance.' Cell Cycle13(11): 1702-1707. Liu, Y., et al. (2013). 'Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis.' Cancer chemotherapy and pharmacology72(5): 1125-1132. Lu, S., et al. (2015). 'The expression of astrocyte elevated gene‐1 in human non‐small‐cell lung cancer and its relationship with postoperative chemotherapy and radiotherapy.' Histopathology67(6): 817-826. Masters, G. A., et al. (2015). 'Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update.' Journal of clinical oncology33(30): 3488-3515. Meng, X., et al. (2013). 'Drug resistance mediated by AEG-1/MTDH/LYRIC.' Advances in cancer research120: 135. Nicolson, M. C., et al. (2013). 'Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non–small-cell lung cancer in a prospective blinded assessment phase II clinical trial.' Journal of thoracic oncology8(7): 930-939. Paz-Ares, L. G., et al. (2013). 'PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non–small-cell lung cancer.' Journal of clinical oncology31(23): 2895-2902. Peters G. J., et al. (2002). “Induction pf thymidylate synthase as 5-fluorouracil resistance mechanism”. Biochim. Biophys. Acta. 1587 (2-3): 194-205 Papamichael D (1999). “The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status”. Oncologist.4(6): 478-87. Santhekadur. P. K. et al. (2012). “Late SV40 factor (LSF) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP-9)”. The Journal of Biological Chemistry. 287 (5): 3425-32. Scagliotti, G. V., et al. (2008). 'Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer.' Journal of clinical oncology26(21): 3543-3551. Shih, C., et al. (1997). 'LY231514, a pyrrolo [2, 3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.' Cancer research57(6): 1116-1123. Shimizu, T., et al. (2016). 'Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.' Clinical and Translational Oncology18(1): 107-112. Siegel, R. L., et al. (2016). 'Cancer statistics, 2016.' CA: a cancer journal for clinicians66(1): 7-30. Song, L., et al. (2009). 'Over‐expression of AEG‐1 significantly associates with tumour aggressiveness and poor prognosis in human non‐small cell lung cancer.' The Journal of pathology219(3): 317-326. Su, Z.-z., et al. (2002). 'Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH.' Oncogene21(22): 3592. Takezawa, K., et al. (2011). 'Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.' British journal of cancer104(10): 1594. Takezawa, K., et al. (2010). 'Identification of thymidylate synthase as a potential therapeutic target for lung cancer.' British journal of cancer103(3): 354. Wang, L., et al. (2014). 'The pemetrexed-containing treatments in the non-small cell lung cancer, is-/low thymidylate synthase expression better than+/high thymidylate synthase expression: a meta-analysis.' BMC cancer14(1): 205. Wang, P., et al. (2014). 'RNA interference-mediated knockdown of astrocyte elevated gene-1 inhibits growth, induces apoptosis, and increases the chemosensitivity to 5-fluorouracil in renal cancer Caki-1 cells.' Molecules and cells37(12): 857. Wang, T., et al. (2013). 'Association between TYMS Expression and Efficacy of Pemetrexed–Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.' PloS one8(9): e74284. Wang, X., et al. (2013). 'Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.' Journal of biomedical science20(1): 5. Yoo, B. K., et al. (2010). 'Molecular mechanism of chemoresistance by astrocyte elevated gene-1.' Cancer research70(8): 3249-3258. Yoo, B. K., et al. (2009). 'Identification of genes conferring resistance to 5-fluorouracil.' Proceedings of the National Academy of Sciences106(31): 12938-12943. 行政院衛生福利部: 105年國人死因統計結果(http://www.mohw.gov.tw/cp-16-33598-1.html) | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/68248 | - |
| dc.description.abstract | 先前的研究發現astrocyte-elevated gene-1(AEG-1)基因表現與各種抗癌化學治療藥物抗藥性產生的機制有關。故本研究用以探討非小細胞肺癌細胞內AEG-1基因的表現量對thymidylate synthase(TS)調控的作用，以及是否因AEG-1的過度表現進而帶動增加TS的表達，因此造成pemetrexed治療後產生抗藥性。本實驗發現在不同的肺癌細胞株內，TS的表現量與AEG-1的表現量同步，TS的表現量愈高者，AEG-1的表現量也愈高。於肺癌細胞株內TS的表現量較低者，pemetrexed藥物的有效半抑制濃度值(IC50)也較低。本研究同時製造了對pemetrexed具有抗藥性的肺癌PC-9細胞株 (PC-9R-A)，證明轉染了AEG-1 siRNA後，AEG-1表現量減少同時降低了TS的表現，也降低了pemetrexedIC50值。相反的當AEG-1基因有過度表現時，則同時增加了TS表現和pemetrexedIC50值。而轉染了TS siRNA後，雖降低了TS表現，也降低了部分pemetrexedIC50值，但對AEG-1的表現量則沒有產生影響，由此推論TS的表現是受到AEG-1之調控。另外在臨床非小細胞患者切片樣本的免疫組織化學染色顯示，癌細胞內TS蛋白質表現量較低的患者，在接受pemetrexed合併鉑類藥物為第一線化學藥物注射時有較佳的治療反應率，而AEG-1蛋白質表現量較低的患者在接受pemetrexed治療時，可擁有較長的無疾病惡化存活期與整體存活時間。此外當肺腺癌患者在接受pemetrexed治療，從一開始有效的治療到發現疾病惡化時，經過再切片樣本組織的分析，從疾病診斷開始到肺癌經治療後再發生惡化時，發現TS表現量的明顯增加，而AEG-1表現量同時也顯著增加。因此綜合以上我們的研究結果顯示，TS的表現可以受到AEG-1表現量的調控，而這些基因表現量的增加，與非小細胞肺癌疾病的惡化有關，並且可能與pemetrexed治療後產生抗藥性相關。 | zh_TW |
| dc.description.abstract | Previous studies have suggested that astrocyte-elevated gene-1(AEG-1) contributes to the mechanisms of resistance to various chemotherapeutics. In this study, we investigated whether AEG-1 expression level correlated with that of thymidylate synthase(TS), as higher TS expression is known to be associated with the resistance to pemetrexed chemotherapy in patients with advanced lung adenocarcinoma. Using pemetrexed-resistant lung adenocarcinoma PC-9 cell line, we demonstrated that transfection of AEG-1 siRNA lowered TS expression and decreased pemetrexed IC50 value. In contrast, overexpression of AEG-1 was associated with increased expression of TS and higher pemetrexed IC50 value. Immunohistochemical staining of clinical biopsy samples showed that patients with lower AEG-1 expression had longer overall survival time. Moreover, analysis of repeated biopsy samples revealed that an increase in the TS level from baseline to disease progression was significantly associated with the elevation of AEG-1 expression. In conclusion, our data demonstrated that TS expression might be regulated by AEG-1 and that increased expression of these proteins contributes to lung cancer disease progression and may be associated with the development of resistance to pemetrexed. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T02:15:42Z (GMT). No. of bitstreams: 1 ntu-106-D03444001-1.pdf: 2448109 bytes, checksum: 0829676b5216886cd5796b7d6c8c32ce (MD5) Previous issue date: 2017 | en |
| dc.description.tableofcontents | 口試委員會審定書 i
誌謝 ii 中文摘要 iii 英文摘要 iv 目錄 v 表目錄 vii 圖目錄 viii 第一章 緒論 1 1-1研究背景與動機 1 1-2研究目的 3 1-3名詞定義 4 1-4研究流程 9 第二章 文獻探討 11 2-1 Thymidylate synthase (TS)的表現在非小細胞肺癌組織中為pemetrexed藥物敏感度的一個決定因素 11 2-2 Astrocyte-elevated gene-1 (AEG-1)可調控thymidylate synthase (TS)的表現 11 第三章 材料與方法 12 3-1實驗材料 12 3-2 實驗方法 16 第四章 研究結果 24 4-1非小細胞肺癌細胞株內AEG-1的表現量與TS的表現量為正相關，而與pemetrexed的藥物感受性呈負相關 24 4-2 以體外實驗利用非小細胞肺癌PC-9細胞株剃除AEG-1基因可回復pemetrexed的抗藥性 24 4-3 AEG-1的過度表現可誘導TS的表現增加造成對pemetrexed的抗藥性 25 4-4 TS和excision repair cross-complementation group 1（ERCC1）的表現程度與使用pemetrexed加鉑治療晚期肺腺癌的治療反應相關 25 4-5 AEG-1的表現影響肺癌的疾病進展和生存期 26 4-6肺腺癌患者在發生pemetrexed抗藥性後AEG-1和TS的表現量增加 27 第五章 討論 28 第六章 參考文獻 31 第七章 圖及表 36 | |
| dc.language.iso | zh-TW | |
| dc.title | Astrocyte-elevated gene-1基因可調控增加thymidylate synthase的過度表現造成非小細胞肺癌pemetrexed治療後產生抗藥性 | zh_TW |
| dc.title | Astrocyte-elevated gene-1 confers resistance to pemetrexed in non-small cell lung cancer by upregulating thymidylate synthase expression | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 106-1 | |
| dc.description.degree | 博士 | |
| dc.contributor.oralexamcommittee | 楊志新,施金元,陳冠宇,何肇基 | |
| dc.subject.keyword | 非小細胞肺癌,pemetrexed,thymidylate synthase,astrocyte elevated gene-1,化學治療藥物抗藥性, | zh_TW |
| dc.subject.keyword | lung cancer,pemetrexed,thymidylate synthase,astrocyte elevated gene-1,chemoresistance, | en |
| dc.relation.page | 50 | |
| dc.identifier.doi | 10.6342/NTU201704265 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2017-10-16 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 病理學研究所 | zh_TW |
| 顯示於系所單位： | 病理學科所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-106-1.pdf 目前未授權公開取用 | 2.39 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。